Navigation Links
ERT Announces the Appointment of Eric Schwartz as Chief Legal Officer
Date:2/22/2011

PHILADELPHIA, Feb. 22, 2011 /PRNewswire/ -- eResearchTechnology, Inc. (ERT or the Company), (Nasdaq: ERES), a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today the appointment of Eric Ian Schwartz as Executive Vice President and Chief Legal Officer effective February 22, 2011.

Mr. Schwartz joins ERT with over 15 years of legal and executive management experience with high growth companies in the healthcare and technology industries.  Most recently, Mr. Schwartz was Assistant General Counsel at Johnson & Johnson, where he served on the senior management teams of several of the fastest growing companies within Johnson & Johnson's medical device and consumer products businesses.  Previously, he was Vice President and General Counsel of Animas Corporation, a public medical devices company, manufacturing and distributing insulin delivery systems for people with diabetes.  Animas was acquired by Johnson & Johnson in 2006.  Mr. Schwartz also held several positions of increasing responsibility with Cable & Wireless Internet Services, Inc., and its predecessor, Digital Island, Inc.  During his career, he has been responsible for a variety of legal, business development, and general management functions.  Mr. Schwartz holds a B.A. and J.D. from the University of Virginia, as well as an MBA from the Wharton School of Business at the University of Pennsylvania.

Joel Morganroth, M.D., Chairman and Interim CEO, commented: "We are all pleased that Eric will be joining the executive management team at ERT.  In his position as Executive Vice President and Chief Legal Officer, he will be responsible for legal affairs, quality assurance, and regulatory compliance, contracts and proposals, and human resources for the Company.  The increased complexity of ERT as a multi-service global company with plans to extend its products and services into adjacent markets makes the addition of a Chief Legal Officer particularly important in achieving the Company's business plans."

About eResearchTechnology, Inc.ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to our operations.  These statements can be identified by the fact that they do not relate strictly to historical or current facts.  They use words such as "aim," "anticipate," "are confident," "estimate," "expect," "will be," "will continue," "will likely result," "project," "intend," "plan," "believe," "look to" and other words and terms of similar meaning in conjunction with a discussion of future operating or financial performance.

These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.  Factors that might cause such a difference include: unfavorable economic conditions; our ability to obtain new contracts and accurately estimate net revenues, our positive outlook for future bookings, variability in size, scope and duration of projects and internal issues at the sponsoring client; our ability to successfully integrate the RS or any future acquisitions; competitive factors in the market for our centralized services; changes in the pharmaceutical, biotechnology and medical device industries to which we sell our solutions; technological development; and market demand.  There is no guarantee that the amounts in our backlog will ever convert to revenue.  Should the economic conditions deteriorate, the cancellation rates that we have historically experienced could increase.  Further information on potential factors that could affect the Company's financial results can be found in ERT's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.  Guidance is based on management's good faith expectations given current market conditions but that continued or further deterioration of general economic conditions, in addition to other factors cited elsewhere, could result in ERT not achieving the revenue and net income per diluted share guidance provided.

Forward-looking statements speak only as of the date made.  We undertake no obligation to update any forward-looking statements, including prior forward-looking statements, to reflect the events or circumstances arising after the date as of which they were made.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included in this release or that may be made in our filings with the Securities and Exchange Commission or elsewhere from time to time by, or on behalf of, us.Media Contacts:Keith Schneck

Robert EasteResearchTechnology, Inc.

Westwicke Partners, LLC215-282-5566

410-321-9652
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
2. Acuo Technologies Announces Another Significant Growth Year in Revenue and Implementations to Further the Companys Market Leading Position
3. Acuo Technologies Announces New Enterprise Capabilities with Latest Software Release
4. SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals
5. Upsher-Smith Laboratories Announces Expansion of Voluntary Nationwide Recall
6. TLC Vision Announces TLC Laser Eye Center San Diego
7. American Scientific Resources Announces New Distributor HospiServices Placing Kidz-Med VeraTemp in Middle Eastern and African Pharmacies
8. Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation
9. Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe
10. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
11. Radiologic Associates of Fredericksburg Announces Image Gently Campaign to Child Size Doses for Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):